Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma
Journal of Clinical Oncology · 20.03.2024 · 42 (9) · 1077-1087
DOI: 10.1200/jco.23.01115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2024. Verfasst von Tomohiro Aoki und 31 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE About a third of patients with relapsed or refractory classic Hodgkin lymphoma (r/r CHL) succumb to their disease after high-dose chemotherapy followed by autologous stem-cell transplantation (HDC/ASCT). Here, we aimed to describe spatially resolved tumor microenvironment (TME) ecosystems to establish novel biomarkers associated with treatment failure in r/r CHL. PATIENTS AND METHODS We performed imaging mass cytometry (IMC) on 71 paired primary diagnostic and relapse biopsies using a marker panel specific to CHL biology. For each cell type in the TME, we calculated a spatial score measuring the distance of nearest neighbor cells to the malignant Hodgkin Reed Sternberg cells within the close interaction range. Spatial scores were used as features in prognostic model development for post-ASCT outcomes. RESULTS Highly multiplexed IMC data revealed shared TME patterns in paired diagnostic and early r/r CHL samples, whereas TME patterns were more divergent in pairs of diagnostic and late relapse samples. Integrated analysis of IMC and single-cell RNA sequencing data identified unique architecture defined by CXCR5 + Hodgkin and Reed Sternberg (HRS) cells and their strong spatial relationship with CXCL13+ macrophages in the TME. We developed a prognostic assay (RHL4S) using four spatially resolved parameters, CXCR5+ HRS cells, PD1+CD4 + T cells, CD68 + tumor-associated macrophages, and CXCR5+ B cells, which effectively separated patients into high-risk versus low-risk groups with significantly different post-ASCT outcomes. The RHL4S assay was validated in an independent r/r CHL cohort using a multicolor immunofluorescence assay. CONCLUSION We identified the interaction of CXCR5+ HRS cells with ligand-expressing CXCL13+ macrophages as a prominent crosstalk axis in relapsed CHL. Harnessing this TME biology, we developed a novel prognostic model applicable to r/r CHL biopsies, RHL4S, opening new avenues for spatial biomarker development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Princess Margaret Cancer Centre-University Health Network, Toronto, Ontario, Canada.
- Cedars-Sinai Medical Center, Los Angeles, CA.
- Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
- Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
ORCID-Profile: Tomohiro Aoki, Aixiang Jiang, Alexander Xu, Alicia Gamboa, Katy Milne, Shanee Chung, Shinya Rai, Mary Warren, Celia Strong, Susana Ben-Neriah, Alina S Gerrie, Aly Karsan, Andrew Roth, Pedro Farinha, David W Scott, Kerry J Savage, Brad H Nelson, Akil Merchant, Christian Steidl
Förderung
- NCI NIH HHS
Zitieren
APA
Aoki, T., Jiang, A., Xu, A., Yin, Y., Gamboa, A., Milne, K., Takata, K., Miyata-Takata, T., Chung, S., Rai, S., Wu, S., Warren, M., Strong, C., Goodyear, T., Morris, K., Chong, L. C., Hav, M., Colombo, A. R., Telenius, A., …, & Steidl, C. (2024). Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. Journal of Clinical Oncology, 42(9), 1077-1087. https://doi.org/10.1200/jco.23.01115
Vancouver
Aoki T, Jiang A, Xu A, Yin Y, Gamboa A, Milne K, et al. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. Journal of Clinical Oncology. 2024;42(9):1077-1087. doi:10.1200/jco.23.01115
BibTeX
@article{Aoki2024,
author = {Aoki, Tomohiro and Jiang, Aixiang and Xu, Alexander and Yin, Yifan and Gamboa, Alicia and Milne, Katy and Takata, Katsuyoshi and Miyata-Takata, Tomoko and Chung, Shanee and Rai, Shinya and Wu, Shaocheng and Warren, Mary and Strong, Celia and Goodyear, Talia and Morris, Kayleigh and Chong, Lauren C and Hav, Monirath and Colombo, Anthony R and Telenius, Adele and Boyle, Merrill and Ben-Neriah, Susana and Power, Maryse and Gerrie, Alina S and Weng, Andrew P and Karsan, Aly and Roth, Andrew and Farinha, Pedro and Scott, David W and Savage, Kerry J and Nelson, Brad H and Merchant, Akil and Steidl, Christian},
title = {Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {9},
pages = {1077--1087},
doi = {10.1200/jco.23.01115}
}
EUVIMED